Addyi
Addyi
- Addyi (flibanserin) is a prescription medicine in Canada and the United States and legitimate pharmacies require a prescription; although some online or unauthorised sellers may claim to supply it without a prescription, purchasing from such sources is unsafe and not recommended.
- Addyi is indicated for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women; flibanserin acts on central neurotransmitters (primarily as a 5‑HT1A agonist and 5‑HT2A antagonist) to increase dopamine and norepinephrine and reduce serotonin, which is thought to modulate sexual desire.
- The usual dose is 100 mg taken orally once daily at bedtime.
- Form of administration: oral tablet (100 mg tablets, typically supplied in blister packs).
- Onset: clinical benefit is not immediate — improvements are usually evaluated over weeks; treatment should be assessed after about 8 weeks to determine efficacy.
- Duration of action: taken once daily with continued dosing for persistent effect; pharmacologic effects are largely confined to the dosing interval (half‑life approximately in the order of hours), and clinical benefit requires ongoing daily therapy.
- Alcohol warning: do not consume alcohol while taking Addyi — concomitant alcohol markedly increases the risk of severe low blood pressure and syncope and is contraindicated by product labelling.
- The most common side effect is dizziness (other frequent adverse effects include sleepiness/somnolence, nausea, insomnia and dry mouth).
- Would you like to try addyi without a prescription?
Basic Addyi Information
- INN (International Nonproprietary Name): Flibanserin
- Brand Names Available In Canada (English): Addyi — Canada (marketed for premenopausal women, 100 mg oral tablets, blister packaging)
- ATC Code: G02CX02 (Other Gynecologicals)
- Forms & Dosages: Tablet, oral — 100 mg — Sprout Pharmaceuticals — Blister packs (usually 30-tablet supply per carton; US, CA)
- Manufacturers In Canada (English): Sprout Pharmaceuticals, Inc. — United States (sole approved supplier as of 2025); no authorised generics as of mid-2025
- Registration Status In Canada (English): Health Canada approval for treatment of acquired, generalized HSDD in premenopausal women
- OTC / Rx Classification: Prescription Only (Rx)
- Standard Dosage: 100 mg orally, once daily at bedtime
- Dosage Adjustments: Not approved for children; not recommended in elderly outside indication; contraindicated in severe hepatic impairment; insufficient data in severe renal impairment
- Typical Treatment Duration & Regimen: Nightly dosing with efficacy assessment at about 8 weeks; discontinue if no benefit by 8 weeks
- Missed Dose / Overdose Guidance: If a dose is missed, skip it and take the next bedtime dose as scheduled; do not double up. Overdose: supportive care and immediate medical attention
- Storage & Transport Guidelines: Store at 20–25°C (68–77°F). Protect from moisture and excessive heat. Keep in original blister packaging
- Absolute Contraindications: Severe hepatic impairment; concomitant use with moderate or strong CYP3A4 inhibitors; known hypersensitivity to flibanserin or excipients
- Relative Contraindications / Cautions: Alcohol use (risk of severe hypotension), use with CNS depressants or certain psychotropic drugs, history of hypotension or syncope
- Common Side Effects: Dizziness, sleepiness (somnolence), nausea, insomnia, dry mouth
- Competitive Landscape: Addyi is the first oral pharmacologic treatment for HSDD in women; alternative approaches include bremelanotide (injectable), off-label testosterone and psychosexual therapies
Availability & Price Landscape
Major National Pharmacy Chains (Shoppers Drug Mart, Rexall, London Drugs)
Where do Canadians usually find Addyi when they need it?
Shelf availability of Addyi (flibanserin 100 mg, 30-tablet blisters) in Canada is concentrated at retail chains that dispense prescription medicines and operate pharmacy services.
Typical stocking points include Shoppers Drug Mart and Rexall in many provinces, Jean Coutu in Quebec, and London Drugs in Western Canada.
Because Addyi is prescription-only and not a commonly reimbursed outpatient drug, individual store stock varies and many pharmacies will order to patient request.
Pharmacies use the product Drug Identification Number (DIN) and supplier details to order and manage inventory.
Online Pharmacy Trends In Canada (Including Provincial Restrictions)
What about buying online?
Licensed Canadian e-pharmacies and pharmacy chains with online services can dispense Addyi with a valid prescription and must follow provincial licensing rules.
Provincial formularies rarely list Addyi routinely, and public coverage is uncommon except via exceptional access or adjudication through specific provincial drug programs.
Online pharmacies operating in Canada must be licensed, and patients should verify pharmacy credentials before ordering.
Fraudulent generics are offered on international websites; as of mid-2025 no authorised generics exist globally, so offers for “cheaper generics” should be treated as suspicious.
Price Ranges By Package Size (With Provincial Differences)
How much will it cost out-of-pocket?
Price ranges depend on province, dispensing fees, and whether private insurance covers HSDD medications.
Expect out-of-pocket costs to be substantially higher in provinces without coverage and when private plans do not list the medication.
Pharmacies typically calculate patient cost from the list price, markup rules, dispensing fee and whether special access or exceptional-case adjudication applies.
Cross-border U.S. purchases are reported among Canadians looking for lower prices, but these carry legal, customs and safety risks and are not recommended.
Canadian Patient Insights & Satisfaction Levels
Forum And Review Platforms (Reddit Canada, HealthBoards, AskDocs)
What are people saying online?
Community posts on Reddit Canada, HealthBoards and AskDocs include firsthand reports from Canadians using Addyi and discussions about access, cost and side effects.
Forum threads often start with questions about where to get a prescription, whether provincial coverage is available, and real-world experiences with the medication.
Reported Benefits And Challenges From Canadian Patients
Do patients notice a difference?
Reported experiences are mixed: some premenopausal women describe meaningful increases in spontaneous desire after consistent nightly dosing, while others report minimal change.
Common patient-reported challenges include daytime sleepiness or dizziness when dosing or when interactions occur, frustration with out-of-pocket cost, and anxiety about alcohol restrictions.
Many patients stress that combining medication with counselling or relationship therapy helped set realistic expectations and improved overall satisfaction.
Canadians also share pharmacy logistics: needing a prescription, variable local store stock and concerns about online offers for unapproved generics.
Patient satisfaction surveys available in public forums show modest average effect sizes but high individual variability, mirroring trial data and clinical guidance that response should be judged by about eight weeks.
- Common Benefits: Increased spontaneous desire for some users; improved partner intimacy when combined with therapy.
- Common Challenges: Daytime somnolence or dizziness, cost burden, alcohol restrictions and supply logistics.
Product Overview & Brand Variants
INN And Brand Names Used In Canada
What is the generic name and how is it sold?
The international nonproprietary name is flibanserin.
The marketed brand in Canada is Addyi, supplied as 100 mg oral tablets in blister packs, typically 30-tablet cartons.
Some non-English e-pharmacy listings may show flibanserin-hydrochloride, but the brand identity in Canada remains Addyi.
Legal Classification Under Health Canada
How is Addyi classified legally?
Addyi is prescription-only (Rx) in Canada.
Health Canada approved the product for acquired, generalized Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women.
The product has a Drug Identification Number (DIN) on market authorisation that pharmacies use for invoicing and formulary checks.
Indications In Local Canadian Medical Practice
Approved Uses (Health Canada DIN Context)
Who is Addyi approved for?
Health Canada approval aligns with clinical-trial indications: acquired, generalized HSDD in premenopausal women.
Clinicians and pharmacists should document the indication when prescribing and may reference the DIN for formulary adjudication and pharmacy records.
Effect is specific to sexual desire; Addyi is not approved to treat arousal disorders, orgasmic disorders or relationship issues by itself.
Off-Label Patterns In Canadian Healthcare
Are there off-label uses?
Off-label use occurs occasionally, for example experimental prescribing in postmenopausal women or combining pharmacotherapy with psychotherapy, but these uses are limited and should be recorded in the clinical chart.
Testosterone preparations or compounded therapies are sometimes tried for libido concerns but are not Health Canada-approved for HSDD and carry different monitoring and safety profiles.
Shared decision-making and documented clinical rationale are important whenever prescribing off-label.
How It Works In The Body
Layman’s Explanation (Canadian Patient-Friendly Tone)
How does Addyi help sexual desire?
Addyi is a daily tablet taken at bedtime that affects brain chemistry involved in sexual desire.
It acts centrally in the brain rather than changing genital blood flow.
By adjusting neurotransmitter balance, some premenopausal women experience modest increases in spontaneous sexual desire.
Clinical Detail From Health Canada Resources
What does it do at a receptor level?
Pharmacologically, flibanserin is a 5-HT1A receptor agonist and a 5-HT2A receptor antagonist, with downstream increases in dopaminergic and noradrenergic signalling and reductions in serotonin activity.
These actions are believed to rebalance neurotransmitters that influence sexual desire in certain patients.
Health Canada labelling emphasises bedtime dosing to reduce daytime somnolence and highlights key interactions such as CYP3A4 inhibitors and alcohol.
Dosage & Administration
Standard Regimens Per Canadian Guidelines
How should Addyi be taken?
The recommended dose is 100 mg orally once daily at bedtime.
Efficacy should be assessed after approximately eight weeks, and if no clinically meaningful benefit is observed, treatment should be discontinued.
Missed-dose instruction: skip a missed dose and take the next dose at the regular bedtime; do not double up.
Adjustments By Patient Type (With Canadian Clinical Notes)
Who needs special caution?
Flibanserin is contraindicated in severe hepatic impairment due to increased exposure and risk.
Concomitant use with moderate or strong CYP3A4 inhibitors should be avoided; examples include certain azole antifungals, some macrolide antibiotics and protease inhibitors.
There are limited data in renal impairment, so exercise caution in severe renal disease.
Not approved for children or for postmenopausal women outside documented off-label use.
| Dosing Topic | Guidance |
|---|---|
| Standard Dose | 100 mg nightly at bedtime |
| Missed Dose | Skip and resume next bedtime dose; do not double |
| Contraindications | Severe hepatic impairment; strong/moderate CYP3A4 inhibitors; hypersensitivity |
| CYP3A4 Examples | Some azoles, certain macrolides, protease inhibitors (avoid concomitant use) |
Contraindications & Side Effects
Common (Health Canada-Approved List)
What side effects are common?
Common adverse events in product labelling include dizziness, somnolence (sleepiness), nausea, insomnia and dry mouth.
These effects are generally mild to moderate and bedtime dosing reduces daytime impairment.
Rare But Serious (With Canadian Pharmacovigilance Data)
What serious problems should patients know about?
Severe hypotension and syncope have been linked to interactions, notably with alcohol and CYP3A4 inhibitors.
Severe hepatic impairment is an absolute contraindication because of increased drug exposure.
Hypersensitivity reactions have been reported and are under regulatory review for potential label updates.
If a patient experiences signs of severe hypotension, fainting, or an allergic reaction (rash, swelling, breathing difficulty), seek immediate medical attention.
Report suspected serious adverse events to Canada Vigilance so regulators and clinicians can assess safety signals.
- Common: Dizziness; sleepiness; nausea; insomnia; dry mouth.
- Serious: Severe hypotension; syncope related to interactions; hypersensitivity; contraindication in severe hepatic impairment.
Comparable Medicines In Canada
Alternatives Table (With DIN References)
What other options exist for HSDD or low desire?
Addyi remains the only oral pharmacologic licensed for HSDD in women as of mid-2025.
| Medicine | Form / Administration | Typical Monitoring |
|---|---|---|
| Addyi (Flibanserin) | Oral, nightly 100 mg | Assess efficacy at 8 weeks; monitor for somnolence, hypotension, interactions |
| Vyleesi (Bremelanotide) | Injectable, on-demand (check current Health Canada status and DIN) | Monitor blood pressure and nausea; differing mechanism and dosing schedule |
| Off-Label Testosterone | Topical or injectable (not Health Canada-approved for HSDD in women) | Requires careful endocrine monitoring; safety concerns over long-term use |
| Non-Pharmacologic | Psychotherapy, couples therapy, sexual counselling | Often first-line or combined approach; no DIN required |
Pros And Cons List
How do options compare in practical terms?
- Addyi: Oral nightly dosing; modest benefit for some; strict interaction and alcohol guidance; no authorised generics as of 2025.
- Vyleesi: On-demand injection; different mechanism; check Canadian authorisation and DIN before prescribing.
- Testosterone (Off-Label): Potential benefit in some cases but lacks Health Canada approval for HSDD and requires endocrine monitoring.
- Therapy: No drug risks; addresses psychological and relationship components; often used in combination with pharmacotherapy.
Current Research & Trends
Major Canadian Or International Studies 2022–2025
What is new in research?
Recent research from 2022 to 2025 emphasises real-world effectiveness, safety surveillance and understanding variability in response.
International cohort analyses and post-marketing surveillance have focused on reports of hypersensitivity and interaction-driven hypotension.
Canadian contributions are primarily case reports and pharmacovigilance entries rather than large registry trials.
Active research areas include integrating pharmacotherapy with psychosexual therapy, searching for biomarkers to predict response, and regulatory watchfulness around fraudulent online products.
- Notable topics: real-world effectiveness, post-marketing safety signals, heterogeneity of treatment response.
- Regulatory watchpoints: patent expiries and interest in authorised generics; as of 2025 no authorised generics validated.
- Research gaps: larger Canadian registries and biomarkers to predict which patients benefit most.
Common Patient Questions In Canada
Here are clear answers to the questions people ask most often.
Can I drink alcohol with Addyi?
No. Alcohol increases the risk of severe hypotension and syncope and labels and guidance advise strict avoidance during treatment and for specified washout periods if instructed.
How long before I see benefit?
Assess response at about eight weeks; some patients notice gradual changes earlier, but an eight-week evaluation is standard.
Will provincial drug plans cover it?
Coverage is rare as a standard listing; exceptional access or private insurance may cover it in some cases. Check provincial formularies (Ontario Drug Benefit, BC PharmaCare, RAMQ) and provide the DIN for adjudication.
Is it safe in pregnancy or breastfeeding?
Safety in pregnancy and breastfeeding is not established; discuss contraception and breastfeeding plans with the prescriber before starting.
Can I buy it online from U.S. pharmacies?
Cross-border purchases carry legal, customs and safety risks, and may lack Canadian labelling and local pharmacovigilance support.
Regulatory Status
Health Canada Approval Process
How was Addyi authorised in Canada?
Health Canada reviewed clinical efficacy and safety data and approved flibanserin for acquired, generalized HSDD in premenopausal women.
Post-marketing surveillance remains active and adverse events are collected through Canada Vigilance.
DIN Number Relevance
Why does the DIN matter?
The Drug Identification Number assigned at market authorisation is the primary identifier pharmacists use for dispensing records, inventory control and insurance billing.
Clinicians and pharmacists should confirm the current DIN and product monograph when prescribing and dispensing.
| Regulatory Action | How It Is Communicated |
|---|---|
| Market Authorisation | Health Canada notice and assignment of DIN |
| Safety Label Changes | Health Canada advisories and updated product monograph |
| Post-Marketing Reports | Canada Vigilance reporting and pharmacovigilance summaries |
Visual Recommendations
Infographic Ideas For Canadian Context
What visuals help patients decide quickly?
Hero visual: product packaging showing a 30-tablet blister with clear Rx-only and 100 mg callouts.
Map visual: provincial coverage heatmap indicating where public formulary coverage is available or rare, with links to ODB, BC PharmaCare and RAMQ where appropriate.
Flowchart: patient suitability checklist covering premenopausal status, hepatic function, interacting medications and alcohol guidance.
Interaction table: quick-reference matrix for CYP3A4 inhibitors, alcohol and CNS depressants.
Safety box: emergency signs (syncope, severe dizziness, hypersensitivity) and steps to report to Canada Vigilance.
Ensure accessibility by including alt text and bilingual labels for materials used in Quebec.
Buying & Storage Advice
In-Store Vs. Online Canadian Purchase Tips
How should Canadians buy Addyi safely?
Always obtain Addyi through a licensed Canadian pharmacy with a valid prescription where required by provincial rules.
Verify the DIN and manufacturer (Sprout Pharmaceuticals) listed on the packaging or pharmacy record.
Be cautious of online offers for “cheaper generics” — as of 2025 no authorised generics exist and fraudulent offers are reported.
For private insurance, confirm plan coverage and pre-authorisation requirements before purchase; for public plans, consider applying for exceptional access if appropriate.
Cross-border purchases from the U.S. carry risks including customs seizure, missing Canadian labelling and difficulty reporting adverse events.
In our online pharmacy, addyi is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.
Proper Storage With Canadian Climate Considerations
How should Addyi be stored at home?
Store at controlled room temperature — 20–25°C (68–77°F) — and protect from moisture and excessive heat.
Keep tablets in the original blister packaging until use to limit humidity exposure.
Do not leave medication in vehicles during winter or summer travel because extreme cold or heat can damage tablets.
- Do: Keep in original blister; store in a cool, dry place indoors.
- Don’t: Expose to direct sunlight, moisture or leave in a car on hot or freezing days.
Guidelines For Proper Use
Canadian Doctor/Pharmacist Advice Style
What should prescribers and pharmacists tell patients?
Confirm the diagnosis: acquired, generalized HSDD in a premenopausal woman and document baseline symptoms.
Perform a baseline medication review to identify CYP3A4 inhibitors and CNS depressants and check hepatic function where indicated.
Discuss alcohol avoidance and contraception if pregnancy is possible.
Provide clear dosing instructions: 100 mg nightly at bedtime, skip missed doses, do not double up.
Arrange follow-up at four to eight weeks for safety checks and assess efficacy at around eight weeks; discontinue if no benefit is observed.
Educate patients on signs of hypotension, syncope and allergic reaction and advise immediate medical attention for severe events.
Encourage reporting of adverse events to Canada Vigilance and provide pharmacy assistance to submit reports if required.
Delivery Across Canada (English)
| City | Region | Delivery time |
|---|---|---|
| Toronto | Ontario | 5-7 days |
| Montreal | Quebec | 5-7 days |
| Vancouver | British Columbia | 5-7 days |
| Calgary | Alberta | 5-7 days |
| Edmonton | Alberta | 5-7 days |
| Ottawa | Ontario | 5-7 days |
| Winnipeg | Manitoba | 5-7 days |
| Halifax | Nova Scotia | 5-9 days |
| Quebec City | Quebec | 5-9 days |
| Surrey | British Columbia | 5-9 days |
| Laval | Quebec | 5-9 days |
| London | Ontario | 5-9 days |
| Victoria | British Columbia | 5-9 days |
| Saskatoon | Saskatchewan | 5-9 days |
| St. John's | Newfoundland and Labrador | 5-9 days |
